ACTIVX FILES IND FOR ANTI-DIABETIC DRUG

ActivX Biosciences has filed an investigational new drug (IND) application with the FDA for KRP-104, a compound for the treatment of Type 2 diabetes. A Phase I clinical trial of KRP-104 commenced on March 3.

KRP-104 is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor that lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.